Nephroprotective Effects of Metformin in Diabetic Nephropathy
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Metformin, a well‐known anti‐diabetic agent, is very effective in lowering blood glucose in patients with type 2 diabetes with minimal side‐effects. Metformin is also being recommended in the treatment of obesity and polycystic ovary syndrome. Metformin elicits its therapeutic effects mainly via activation of AMP‐activated kinase (AMPK) pathway. Renal cells under hyperglycemic or proteinuric conditions exhibit inactivation of cell defense mechanisms such as AMPK and autophagy, and activation of pathologic pathways such as mammalian target of rapamycin (mTOR), endoplasmic reticulum (ER) stress, epithelial‐to‐mesenchymal transition (EMT), oxidative stress, and hypoxia. As these pathologic pathways are intertwined with AMPK signaling, the potential benefits of metformin therapy in patients with type 2 diabetes would extend beyond its anti‐hyperglycemic effects. However, since metformin is eliminated unchanged through the kidneys and some studies have shown the incidence of lactic acidosis with its use during severe renal dysfunction, the use of metformin was contraindicated in patients with renal disease until recently. With more studies indicating the relatively low incidence of lactic acidosis and revealing the additional benefits with metformin therapy, the US FDA has now approved metformin to be administered in patients with established renal disease based on their renal function. The purpose of this review is to highlight the various mechanisms by which metformin protects renal cells that have lost its functionality in a diabetic or non‐diabetic setting and to enlighten the advantages and therapeutic potential of metformin as a nephroprotectant for patients with diabetic nephropathy and other non‐diabetic forms of chronic kidney disease. J. Cell. Physiol. 232: 731–742, 2017. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 9×
“[UVRAG- UV-radiation associated gene]. mTOR is one of the most important nutrient-sensing pathways within cells. mTORC1 and mTORC2 complexes of mTOR negatively regulate autophagy by inhibiting the initiation of formation of PAS via direct phosphorylation of ULK1 (Lee et al., 2010; Kim et al., 2011).”
BackgroundInfluentialOxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 2×
“Shaw et al. (2005) showed that deletion of LKB1 in hepatocytes of adult mice significantly reduced AMPK activity indicating the importance of LKB1 in AMPK signaling.”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 1×
“Metformin does not appear to bind to any hepatic or plasma proteins (Graham et al., 2011).”
BackgroundMetformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889 · cited 1×
“Metformin has been shown to effectively activate AMPK in renal cells (Lee et al., 2007) but does it directly inhibit mTOR pathway independent of AMPK activation (Kalender et al., 2010) is an area to be researched on.”
BackgroundStabilization of HIF-1α is critical to improve wound healing in diabetic mice
Botusan, I. R., Sunkari, V. G., Savu, O., Catrina, A. I., Grünler, J., Lindberg, S., Pereira, T., Ylä-Herttuala, S., Poellinger, L., Brismar, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805230105 · Cited by 533 · cited 2×
“HIF-1a plays an important role in wound healing via expression of multiple angiogenic growth factors, recruitment of progenitor cells and cell motility (Botusan et al., 2008).”
BackgroundThe Association of AMPK with ULK1 Regulates Autophagy
Lee, J. W., Park, S., Takahashi, Y., & Wang, H.-G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015394 · Cited by 482
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Role of Advanced Glycation End Products in Diabetic Nephropathy
Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077413.41276.17 · Cited by 351 · cited 1×
“AGEs also stimulate the production of extracellular matrix proteins and interact with the renin-angiotensin system (Forbes et al., 2003).”
BackgroundActivating AMP-activated protein kinase (AMPK) slows renal cystogenesis
Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S., & Caplan, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011498108 · Cited by 345
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2594 · Cited by 312
Autophagy in diabetic nephropathy
Ding, Y., & Choi, M. E. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0437 · Cited by 306
Stephenne, X., Foretz, M., Taleux, N., van der Zon, G. C., Sokal, E., Hue, L., Viollet, B., & Guigas, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2311-5 · Cited by 287 · cited 6×
“AMPK acts as a fuel sensor and a master regulator of energy homeostasis in many organs and tissues by inhibiting anabolic pathways and stimulating catabolic pathways (Stephenne et al., 2011).”
BackgroundInfluentialAutophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury
Liu, S., Hartleben, B., Kretz, O., Wiech, T., Igarashi, P., Mizushima, N., Walz, G., & Huber, T. B. (2012) · Autophagy · doi:10.4161/auto.19419 · Cited by 271 · cited 2×
“…damaged cellular components are taken up by autophagosomes, which subsequently fuse with lysosomes to form autolysosomes, the ultimate autophagy apparatus that mediates lysosomal degradation to maintain cell survival and cellular metabolism (Liu et al., 2012; Inoki, 2014; Liu et al., 2014).”
BackgroundMeta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.22.14048 · Cited by 216 · cited 2×
“Their study concluded that metformin attenuates the activity of TGFb by reducing the accumulation of mesenchymal marker vimentin in MDCK cells (Cufi et al., 2010).”
BackgroundCheng, M., Liu, H., Zhang, D., Liu, Y., Wang, C., Liu, F., & Chen, J. (2015) · American Journal of Nephrology · doi:10.1159/000381464 · Cited by 66 · cited 1×
“…glycosylation end products (AGE) formed under hyperglycemic conditions are shown to activate the receptor of advanced glycation end products (RAGE) and promote the expression of growth factors such as TGF-b1 and CTGF in renal proximal tubular cells and result in renal fibrosis (Cheng et al., 2015).”
Background
Cited by
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Han, Y.-C., Tang, S.-Q., Liu, Y.-T., Li, A.-M., Zhan, M., Yang, M., Song, N., Zhang, W., Wu, X.-Q., Peng, C.-H., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04184-8 · Cited by 257
Primary Cilia as a Signaling Platform for Control of Energy Metabolism
Song, D. K., Choi, J. H., & Kim, M.-S. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.42.2.117 · Cited by 42
“The anti-diabetic drug metformin and mTOR inhibitor rapamycin have been shown to arrest cyst epithelial cell proliferation and suppress cyst growth [32,33].”
BackgroundZhao, C., Pu, Z., Gao, J., Liu, C., Xing, J., Lang, W., Chen, J., Yuan, C., & Zhou, C. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05595 · Cited by 26
Metadata
- Authors
- Ravindran, S., Kuruvilla, V., Wilbur, K., & Munusamy, S.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2016-09-26
- Volume
- 232
- Issue
- 4
- Pages
- 731-742
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2528573427
- Cited by
- 132
- References
- 18
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.